Maximum quantity allowed is 999
请选择数量
CAS RN: 16676-29-2 | 產品號碼: N1176
Naltrexone Hydrochloride
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | N1176 |
| 純度/分析方法 | >98.0%(GC)(HPLC) |
| 分子式 / 分子量 | C__2__0H__2__3NO__4·HCl = 377.87 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Hygroscopic,Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片）, 250MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 16676-29-2 |
| Reaxys-RN | 3580333 |
| PubChem Substance ID | 468592499 |
| MDL編號 | MFCD00069324 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Water | max. 11.0 % |
性質
| 熔點 | 178 °C |
| 水溶性 | Soluble |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
| RTECS # | QD2160000 |
運輸資料
| HS編碼* | 2939.19-000 |
Application
Naltrexone Hydrochloride: A Long Acting Competitive Peripheral μ-Opioid Antagonist
Naltrexone hydrochloride, a long acting competitive peripheral μ-opioid antagonist, is a synthetic congener of opioid analgesics with little or no μ-opioid agonist properties.1) It is used for the treatment of opioid dependence and opioid-induced constipation, and is also used for alcohol dependence in US and EU.2,3) Recently, μ-opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. Therefore, the μ-opioid antagonist naltrexone has received attention as a new anticancer agent with few side-effects (low-dose naltrexone, LDN).4,5) (The product is for research purpose only.)
References
- 1) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
- 2) Alteration of ethanol self-administration by naltrexone
- 3) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence (a review)
- 4) The opioid growth factor-opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease (a review)
- 5) Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy (a review)
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。